EU Signs Contract for 2.25 Million Veklury COVID-19 Treatments
EU Secures Millions of COVID-19 Treatment Vials for Member States
Brussels, Belgium – In a move to bolster its pandemic preparedness, the European Commission has secured a significant supply of Veklury (Remdesivir), a key antiviral treatment for COVID-19. The European Union’s Health Emergency Preparedness adn Response Authority (HERA) signed a joint procurement framework contract with pharmaceutical giant Gilead on Monday, guaranteeing access to 2.25 million vials for 13 EU member states.
[Image: A healthcare worker administers an injection to a patient. (Source: Pexels)]
This latest agreement, the third of its kind, will ensure a steady supply of Veklury for the next three years, replacing the previous contract that expired in January 2024. Veklury is authorized for use in hospitalized adult and adolescent patients with COVID-19 who require supplemental oxygen, and also adults at high risk of developing severe illness.
“Joint procurement is a vital tool in our arsenal against public health threats,” said a HERA spokesperson. “This mechanism allows EU member states to pool their resources and secure essential medical countermeasures like Veklury, ensuring equitable access for all citizens.”
Joint procurement allows the 37 countries participating in the Joint Procurement Agreement to collectively purchase medical supplies, offering a more efficient and cost-effective approach compared to individual national procurement.This collaborative effort strengthens the EU’s ability to respond effectively to pandemics and other health emergencies.
HERA continues to work closely with member states to identify and prioritize future joint procurement needs, ensuring the EU remains well-prepared to face evolving health challenges.
Securing the Future: EU Stocks Up on COVID-19 Treatment
Brussels, Belgium – In a proactive move to ensure adequate pandemic preparedness, the European Commission has secured a substantial supply of Veklury (Remdesivir), a vital antiviral medication used to treat COVID-19. This agreement, brokered through the European Union’s Health Emergency Preparedness and Response Authority (HERA), guarantees 2.25 million vials of Veklury for 13 EU member states over the next three years.
This latest procurement deal, the third of its kind, replaces the existing contract expiring in January 2024 and ensures a consistent supply of the crucial medication. veklury is authorized for use in hospitalized adult and adolescent patients with COVID-19 who require supplemental oxygen, as well as for adults at high risk of developing severe illness.
“Joint procurement is a cornerstone of our strategy for combating public health threats,” stated a HERA spokesperson.”This mechanism empowers EU member states to pool thier resources and acquire essential medical countermeasures like Veklury, guaranteeing equitable access for all citizens.”
Joint procurement, wich involves 37 participating countries, offers a more efficient and cost-effective approach to securing medical supplies compared to individual national procurement. This collaborative effort enhances the EU’s ability to respond effectively to pandemics and other health emergencies.
HERA remains committed to working closely with member states to identify and prioritize future joint procurement needs, ensuring the EU stays prepared to confront emerging health challenges.